Drug Trial Radar · NCT05477576
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
343
Actual
Start
Mar 24, 2022
Primary completion
Dec 2026
Study completion Dec 2030
Sponsor
- Lead sponsor
- RayzeBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity \[HA\]-DOTATATE.
Conditions
- GEP-NET
- Gastroenteropancreatic Neuroendocrine Tumor
- Gastroenteropancreatic Neuroendocrine Tumor Disease
- Neuroendocrine Tumors
- Carcinoid
- Carcinoid Tumor
- Pancreatic NET
Interventions
RYZ101Drug
RP3D as determined in Phase 1b
EverolimusDrug
Everolimus
SunitinibDrug
Sunitinib
OctreotideDrug
High-dose octreotide
LanreotideDrug
Lanreotide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: RP3DTime frame: 56 days of study treatment
- Phase 3: PFS as determined by BICRTime frame: After the target number of 143 PFS events have occurred
Locations
54 sites in 8 countries. Site status is shown where the registry gives one.
Research Facility
Phoenix, Arizona
Research Facility
Duarte, California
Research Facility
Irvine, California
Research Facility
Los Angeles, California
Research Facility
Palo Alto, California
Research Facility
San Francisco, California
Research Facility
New Haven, Connecticut
Research Facility
Washington D.C., District of Columbia
Research Facility
Jacksonville, Florida
Research Facility
Miami, Florida
Research Facility
Tampa, Florida
Research Facility
Atlanta, Georgia
Research Facility
Iowa City, Iowa
Research Facility
Lexington, Kentucky
Research Facility
Glen Burnie, Maryland
Research Facility
Boston, Massachusetts
Research Facility
Boston, Massachusetts
Research Facility
Troy, Michigan
Research Facility
Rochester, Minnesota
Research Facility
St Louis, Missouri
Research Facility
Omaha, Nebraska
Research Facility
New York, New York
Research Facility
New York, New York
Research Facility
Cleveland, Ohio
Research Facility
Columbus, Ohio
Research Facility
Portland, Oregon
Research Facility
Philadelphia, Pennsylvania
Research Facility
Pittsburgh, Pennsylvania
Research Facility
Nashville, Tennessee
Research Facility
Houston, Texas
Research Facility
Salt Lake City, Utah
Research Facility
Seattle, Washington
Research Facility
Brussels, Belgium
Research Facility
Leuven, Belgium
Research Facility
Roeselare, Belgium
Research Facility
Brasília, Brazil
Research Facility
Rio de Janeiro, Brazil
Research Facility
São Paulo, Brazil
Research Facility
London, Ontario, Canada
Research Facility
Toronto, Ontario, Canada
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.